Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ETNB 89BIO	$10.49 -1.5%	$9.79	$4.16 ▼ $11.84	$1.53B	1.28	1.54 million shs	1.31 million shs
JANX Janux Therapeutics	$26.40 -4.9%	$24.62	$22.48 ▼ $71.71	$1.56B	2.86	878,789 shs	908,736 shs
SDGR Schrodinger	$21.45 -0.9%	$21.94	$16.60 ▼ $28.47	$1.57B	1.58	928,386 shs	962,275 shs
TECX Tectonic Therapeutic	$21.91 -5.9%	$21.65	$13.70 ▼ $61.07	$409.13M	3.17	191,884 shs	88,882 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ETNB 89BIO	0.00%	-4.64%	+4.90%	+73.10%	+20.85%
JANX Janux Therapeutics	0.00%	+4.97%	+16.20%	-11.08%	-39.88%
SDGR Schrodinger	0.00%	+2.09%	+1.90%	-16.70%	-7.42%
TECX Tectonic Therapeutic	0.00%	-3.22%	+10.66%	+28.73%	+26.43%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ETNB 89BIO	2.1482 of 5 stars	3.5	1.0	3.2	0.8	0.6
JANX Janux Therapeutics	2.2554 of 5 stars	3.5	1.0	3.0	2.5	0.0
SDGR Schrodinger	2.0363 of 5 stars	3.4	1.0	2.4	1.7	0.6
TECX Tectonic Therapeutic	2.2608 of 5 stars	3.7	1.0	0.6	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ETNB 89BIO	3.00	Buy	$26.43	151.94% Upside
JANX Janux Therapeutics	3.08	Buy	$91.89	248.06% Upside
SDGR Schrodinger	2.75	Moderate Buy	$32.75	52.68% Upside
TECX Tectonic Therapeutic	3.33	Buy	$83.60	281.56% Upside

Current Analyst Ratings Breakdown

Latest TECX, ETNB, JANX, and SDGR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	SDGR Schrodinger	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$32.00 ➝ $30.00
7/12/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
7/11/2025	JANX Janux Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$65.00
7/3/2025	SDGR Schrodinger	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$28.00
6/27/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
6/11/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
6/11/2025	TECX Tectonic Therapeutic	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$76.00
6/6/2025	TECX Tectonic Therapeutic	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$87.00
6/5/2025	TECX Tectonic Therapeutic	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/24/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
5/15/2025	TECX Tectonic Therapeutic	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$51.00 ➝ $85.00

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ETNB 89BIO	N/A	N/A	N/A	N/A	$3.34 per share	N/A
JANX Janux Therapeutics	$10.59M	147.51	N/A	N/A	$19.49 per share	1.35
SDGR Schrodinger	$207.54M	7.58	N/A	N/A	$5.78 per share	3.71
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	$9.54 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ETNB 89BIO	-$367.08M	-$3.38	N/A	N/A	N/A	N/A	-81.44%	-70.17%	8/4/2025 (Estimated)
JANX Janux Therapeutics	-$68.99M	-$1.36	N/A	N/A	N/A	N/A	-9.29%	-8.89%	8/6/2025 (Estimated)
SDGR Schrodinger	-$187.12M	-$2.63	N/A	N/A	N/A	-83.39%	-44.74%	-26.29%	7/30/2025 (Estimated)
TECX Tectonic Therapeutic	-$57.98M	-$7.31	N/A	N/A	N/A	N/A	-30.13%	-27.52%	8/13/2025 (Estimated)

Latest TECX, ETNB, JANX, and SDGR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	TECX Tectonic Therapeutic	-$0.98	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	JANX Janux Therapeutics	-$0.50	N/A	N/A	N/A	$0.30 million	N/A
8/4/2025	Q2 2025	ETNB 89BIO	-$0.49	N/A	N/A	N/A	N/A	N/A
7/30/2025	Q2 2025	SDGR Schrodinger	-$0.83	N/A	N/A	N/A	$52.03 million	N/A
5/8/2025	Q1 2025	JANX Janux Therapeutics	-$0.43	-$0.38	+$0.05	-$0.38	$0.59 million	N/A
5/8/2025	Q1 2025	TECX Tectonic Therapeutic	-$1.10	-$0.93	+$0.17	-$0.93	N/A	N/A
5/7/2025	Q1 2025	SDGR Schrodinger	-$0.81	-$0.82	-$0.01	-$0.82	$54.60 million	$59.55 million
5/1/2025	Q1 2025	ETNB 89BIO	-$0.50	-$0.49	+$0.01	-$0.49	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ETNB 89BIO	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A
SDGR Schrodinger	N/A	N/A	N/A	N/A	N/A
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ETNB 89BIO	0.06	18.03	18.03
JANX Janux Therapeutics	N/A	58.47	58.47
SDGR Schrodinger	N/A	3.45	3.45
TECX Tectonic Therapeutic	N/A	22.92	22.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ETNB 89BIO	N/A
JANX Janux Therapeutics	75.39%
SDGR Schrodinger	79.05%
TECX Tectonic Therapeutic	62.63%

Insider Ownership

Company	Insider Ownership
ETNB 89BIO	2.60%
JANX Janux Therapeutics	8.10%
SDGR Schrodinger	8.60%
TECX Tectonic Therapeutic	38.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ETNB 89BIO	40	145.98 million	142.19 million	Optionable
JANX Janux Therapeutics	30	59.17 million	54.38 million	Optionable
SDGR Schrodinger	790	73.38 million	67.07 million	Optionable
TECX Tectonic Therapeutic	120	18.67 million	11.58 million	N/A

TECX, ETNB, JANX, and SDGR Headlines

Recent News About These Companies

Tectonic Therapeutic (NASDAQ:TECX) Upgraded to "Hold" at Wall Street Zen

July 5, 2025 | marketbeat.com

Tectonic Therapeutic, Inc. (NASDAQ:TECX) Receives Average Recommendation of "Buy" from Brokerages

July 3, 2025 | marketbeat.com

Tectonic Therapeutic, Inc. Added to Russell 3000® Index Following Annual Reconstitution - Nasdaq

July 1, 2025 | nasdaq.com

Tectonic Therapeutic joins Russell 3000 index

June 30, 2025 | msn.com

Tectonic Therapeutic, Inc. Added to Russell 3000® Index Following Annual Reconstitution

June 30, 2025 | quiverquant.comQ

Tectonic Therapeutic Joins Russell 3000® Index

June 30, 2025 | globenewswire.com

Raymond James Resumes Coverage of Tectonic Therapeutic (TECX) With an Outperform Rating

June 25, 2025 | msn.com

Tectonic Therapeutic (NASDAQ:TECX) Stock Rating Lowered by Wall Street Zen

June 21, 2025 | marketbeat.com

We Think Tectonic Therapeutic (NASDAQ:TECX) Can Afford To Drive Business Growth

June 15, 2025 | finance.yahoo.com

Tectonic Therapeutics (TECX) Gains Outperform Rating from Raymond James | TECX Stock News

June 10, 2025 | gurufocus.com

LifeSci Capital Initiates Coverage of Tectonic Therapeutic (TECX) with Outperform Recommendation

June 7, 2025 | msn.com

Tectonic Therapeutic Holds 2025 Annual Stockholders Meeting

June 6, 2025 | tipranks.com

Tectonic Therapeutic (TECX) Receives Outperform Rating and $87 Price Target | TECX Stock News

June 5, 2025 | gurufocus.com

Tectonic Therapeutic Reports Q1 2025 Financial Results

May 30, 2025 | tipranks.com

Promising Phase 1b Results and Market Potential Drive Buy Rating for Tectonic Therapeutic’s TX45

May 22, 2025 | tipranks.com

Tectonic Therapeutic Announces Phase 1b Trial Results

May 19, 2025 | tipranks.com

Promising Phase 1b Results and Favorable Safety Profile Justify Buy Rating for Tectonic Therapeutic

May 19, 2025 | tipranks.com

Analysts Offer Insights on Healthcare Companies: Tectonic Therapeutic (TECX) and Amgen (AMGN)

May 17, 2025 | theglobeandmail.com

Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in ...

May 17, 2025 | gurufocus.com

Tectonic Therapeutic Reports Positive Phase 1b Results for TX45 in Group 2 Pulmonary Hypertension Patients with Heart Failure and Preserved Ejection Fraction

May 17, 2025 | quiverquant.comQ

Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure

May 17, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TECX, ETNB, JANX, and SDGR Company Descriptions

89BIO NASDAQ:ETNB

$10.49 -0.16 (-1.50%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$10.61 +0.12 (+1.14%)

As of 07/18/2025 05:27 PM Eastern

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

Janux Therapeutics NASDAQ:JANX

$26.40 -1.35 (-4.86%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$26.40 +0.01 (+0.02%)

As of 07/18/2025 06:53 PM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Schrodinger NASDAQ:SDGR

$21.45 -0.20 (-0.92%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$21.74 +0.29 (+1.33%)

As of 07/18/2025 07:57 PM Eastern

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Tectonic Therapeutic NASDAQ:TECX

$21.91 -1.37 (-5.88%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$21.96 +0.05 (+0.25%)

As of 07/18/2025 04:32 PM Eastern

Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time